Lacosamide G.L Pharma

Lacosamide, the active ingredient in Lacosamide G.L Pharma, is an antiepileptic presented as a tablet for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy. GNH USA supplies Lacosamide G.L Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug used to manage focal seizure activity in epilepsy. - Partial‑onset seizures: reduces seizure frequency as monotherapy or adjunct therapy. - Adjunct therapy for epilepsy: added when seizures are not adequately controlled by other agents. - Focal epilepsy: improves overall seizure control in patients with focal seizure types.

Lacosamide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild to moderate gastrointestinal upset. - Headache: occasional tension‑type headache. - Fatigue: feeling of reduced energy or tiredness. - Vision changes: blurred or double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: PR‑interval prolongation or other conduction abnormalities. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: emergence of thoughts of self‑harm.

Before prescribing Lacosamide, clinicians should consider several safety aspects. - Cardiac monitoring: assess ECG for PR‑interval prolongation, especially in patients with cardiac disease. - Renal function: adjust use in severe renal impairment as drug clearance may be reduced. - Hepatic function: monitor liver enzymes in patients with hepatic dysfunction. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy and lactation: evaluate risk‑benefit ratio; limited data are available. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may markedly reduce lacosamide plasma levels. - Concomitant use with other sodium‑channel blockers (e.g., lamotrigine, oxcarbazepine): increased risk of cardiac conduction effects.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may increase lacosamide exposure. - Anticoagulants (e.g., warfarin): may require INR monitoring. - Alcohol: can enhance central nervous system depression.